2023
Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up
Becerra L, Gavrieli A, Khan F, Novak P, Lioutas V, Ngo L, Novak V, Mantzoros C. Daily intranasal insulin at 40IU does not affect food intake and body composition: A placebo-controlled trial in older adults over a 24-week period with 24-weeks of follow-up. Clinical Nutrition 2023, 42: 825-834. PMID: 37084469, PMCID: PMC10330069, DOI: 10.1016/j.clnu.2023.04.008.Peer-Reviewed Original ResearchConceptsBody mass indexType 2 diabetesIntranasal insulinSecondary outcomesFood intakeBody compositionType 2 diabetes trialsOlder adultsPlacebo-controlled studyPlacebo-controlled trialDiabetes (ACCORD) trialPrimary outcomeIntervention visitsMass indexBody fatAnthropometric measuresAnimal studiesBody weightHigh dosesInteraction of treatmentEnergy homeostasisDiabetesInsulinWeight lossAppetite
2022
Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial.
Aponte Becerra L, Galindo Mendez B, Khan F, Lioutas V, Novak P, Mantzoros C, Ngo L, Novak V. Safety of Intranasal Insulin in Type 2 Diabetes on Systemic Insulin: A Double-Blinded Placebo-Controlled Sub-Study of Memaid Trial. Archives Of Diabetes & Obesity 2022, 4: 403-415. PMID: 35903156, PMCID: PMC9328174.Peer-Reviewed Original ResearchContinuous glucose monitoringIntranasal insulinGlycemic variabilitySystemic insulinAdverse eventsPlacebo treatmentHypoglycemic episodesWeight gainDouble-blinded placeboSerious adverse eventsDouble-blinded trialType 2 diabetesSubcutaneous insulinDiabetes burdenPlasma glucoseCapillary glucoseInsulin sensitivitySub studyLong-term effectsSafety outcomesTrial participantsGlucose metabolismShort-term effectsInsulinDiabetes